Symbravo meloxicam, rizatriptan 20 mg; 10 mg Tablet, 2-count — NDC 81968-020-02 (Billing 81968-0020-02)
This is a package of 2 tablets of Symbravo meloxicam, rizatriptan 20 mg; 10 mg Tablet from Axsome Therapeutics, Inc., first listed with the FDA May 2025 and currently FDA-listed.
NDC database record
One package, one record: these facts belong to NDC 81968-020-02 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 81968 labeler · 020 product · 02 package
- Package marketed since
- Nov 21, 2025
- Sample package
- Yes — professional sample, not for sale
- Listing certified through
- Dec 31, 2027
- Barcode (UPC)
- 0381968020034, 0381968020096
- FDA record last changed
- Nov 12, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 087178
- GCN: 57005
- HICL (First Databank): 050252
- AHFS class code: 28:08.04.04
- RxCUI (RxNorm): 2711789
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 19, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
RxNorm drug class
This medicine belongs to the Nonsteroidal Anti-inflammatory Drug class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Nov 19, 2026
Clinical
Meloxicam and rizatriptan is used to treat the symptoms of migraine headaches. Meloxicam is in a class of medications called nonsteroidal anti-inflammatory drugs (NSAIDs). It works by stopping the body's production of a substance that causes pain and inflammation. Rizatriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and blocking the release of certain natural substances that cause pain, nausea, and other symptoms of migraine. Meloxicam and rizatriptan does n...
Read the full MedlinePlus article ↗- It treats a migraine attack in adults once it has started, with or without aura. It does not prevent migraines and is not for cluster headache. It should be used only when migraine...
- What is Meloxicam / Rizatriptan (SYMBRAVO) used for?
- You take one tablet by mouth when a migraine begins. Swallow it whole without crushing, splitting or chewing. You can take it with or without food. Do not take more than one tablet...
- The label says the safety and effectiveness of a second dose for the same attack have not been established, and the daily limit is one tablet. If it isn't working, talk with your p...
Patient education
Drug interactions
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 19, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Oct 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Per unit | Per pack | Marketing start | Marketing end | Status |
|---|---|---|---|---|---|---|
| 81968-0020-02 You're viewing this | 1 BOTTLE in 1 CARTON / 2 TABLET in 1 BOTTLE Sample | — | — | 2025-11-21 | — | Active |
| 81968-0020-03 81968-020-03 | 1 BOTTLE in 1 CARTON / 3 TABLET in 1 BOTTLE Sample | — | — | 2025-05-19 | — | Active |
| 81968-0020-09 81968-020-09 Main listing | 9 TABLET in 1 BOTTLE | $122.52 / ea | $1,102.67 | 2025-05-19 | — | Active |
This pack shows little to no recent Medicaid volume — the 9 tablets pack carries most fills. See all packs ↓
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 81968-0020-03?
What NDC number is used to bill for this package of Symbravo meloxicam, rizatriptan 20 mg; 10 mg Tablet?
Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Symbravo 20 mg/1; 10 mgthis 81968-0020-02 | Axsome | 2 tablets | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route. Patent/protection dates below may affect future generic timing.
Why the date isn’t exact: Generic timing can change because patents may be challenged, settled, licensed, added, removed, or worked around with a narrower label — and FDA approval does not always mean a pharmacy can get the generic today.
Our estimate: May 2040 about 13.5 years away
How sure: Probable. More likely than not, but it can still move.
Why then: A patent that protects the brand runs out. After that, approved generics can be sold.
That is before the March 2045 date above, which is common: a court ruling or a deal with the brand’s maker often lets a generic in before the last patent runs out.
See the full forecast for generic Symbravo →🛈 What do these terms mean?
- Patent
- Legal protection listed in the Orange Book that may delay generic approval or launch. Issued by the U.S. Patent & Trademark Office.
- Substance patent
- Covers the active drug molecule itself — the hardest to design around. A generic generally can’t launch until it expires.
- Formulation (product) patent
- Covers a specific formulation or dosage form. A generic can sometimes work around it with a different formulation.
- Method-of-use patent
- A patent covering one specific approved use of the drug — not necessarily the whole molecule. A generic can sometimes launch with a “skinny label” that carves out the protected use and keeps the others.
- Skinny label
- A generic label that omits a still-patented use when the FDA allows it — letting a generic reach the market for the unprotected uses.
- Exclusivity
- FDA-granted marketing protection, separate from patents — e.g. 5-yr new chemical entity, 7-yr orphan drug, or a +6-month pediatric extension.
- Paragraph IV
- A generic applicant’s formal challenge to a listed patent. It can potentially lead to earlier generic entry, but often involves litigation or a settlement.
- RLD / RS
- Reference Listed Drug — the brand product the FDA uses as the reference for generic applications. Reference Standard — the product the FDA expects generics to compare against in bioequivalence testing.
- TE / AB rating
- FDA therapeutic-equivalence rating. An AB rating generally means the FDA considers a generic therapeutically equivalent to — and substitutable for — the brand.
- LOE (loss of exclusivity)
- The latest patent or exclusivity currently listed — the loss-of-exclusivity / latest-listed-protection date shown on this page. Paragraph-IV challenges and settlements can move the real date earlier; FDA approval and a manufacturer’s decision to market can move it later.
Built from the FDA Orange Book. The bars above are scaled to each protection’s expiry; the red LOE marker is the last one to lapse.
| Patent | Type | Use code | Expires |
|---|---|---|---|
| US 12551489 ↗ | Method of use | U-1719 | May 28, 2040 |
| US 12551488 ↗ | Method of use | U-1719 | May 28, 2040 |
| US 12544383 ↗ | Method of use | U-1719 | Mar 10, 2045 |
| US 10702535 ↗ | Method of use | U-4136 | Apr 11, 2036 |
| US 10702602 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11013806 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10722583 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 12128052 ↗ | Method of use | U-1719 | May 28, 2040 |
| US 10987358 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10729696 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10688102 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11865117 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10729697 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11617755 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10729773 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10517950 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11426414 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 9821075 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10029010 ↗ | Method of use | U-4133 | Apr 11, 2036 |
| US 10137131 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10195278 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10695429 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10265324 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11369684 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10695430 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10363312 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10688185 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10653777 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10583144 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11331323 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10561664 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10537642 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10369224 ↗ | Method of use | U-4134 | Apr 11, 2036 |
| US 10532101 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11285213 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10426839 ↗ | Method of use | U-4135 | Apr 11, 2036 |
| US 10471014 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11219626 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10471069 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10512692 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11207328 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10512693 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11135295 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11045549 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11020483 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11826370 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10940153 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11602563 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11806354 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11510927 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10933137 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11504429 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11471464 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10933136 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11801250 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10799588 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10780165 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10821181 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11759522 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10758618 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10918722 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11738085 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11013805 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11712441 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10905693 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11628173 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10894053 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11617791 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10821182 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11617756 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11607456 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11571428 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11471465 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10780166 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10758617 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 12472257 ↗ | Method of use | U-4134 | May 18, 2038 |
| US 12472256 ↗ | Method of use | U-4356 | May 18, 2038 |
| US 12485176 ↗ | Method of use | U-4133 | Apr 11, 2036 |
| US 12370196 ↗ | Method of use | U-1719 | Dec 29, 2041 |
| US 10265400 ↗ | Method of use | U-4509 | Apr 11, 2036 |
| US 10265399 ↗ | Method of use | U-4509 | Apr 11, 2036 |
| US 10307484 ↗ | Method of use | U-4509 | Apr 11, 2036 |
| US 10369225 ↗ | Method of use | U-4356 | Apr 11, 2036 |
| US 10456471 ↗ | Method of use | U-4509 | Apr 11, 2036 |
| US 11266657 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11433078 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11433079 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 11944683 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 12611413 ↗ | Method of use | U-1719 | Dec 29, 2041 |
| US 12005118 ↗ | Method of use | U-1719 | Jan 25, 2043 |
| US 12616752 ↗ | Method of use | U-4510 | May 18, 2038 |
| US 12685736 ↗ | Method of use | U-1719 | May 9, 2040 |
| US 12691123 ↗ | Method of use | U-1719 | Apr 11, 2036 |
| US 10058614 ↗ | Drug product | — | Apr 11, 2036 |
| US 10463736 ↗ | Drug product | — | Apr 11, 2036 |
| US 12472258 ↗ | Drug product | — | May 18, 2038 |
| Code | What it grants | Expires |
|---|---|---|
| NP | New Product | Jan 30, 2028 |
Is there a generic version of SYMBRAVO 20-10 MG TABLET?
The FDA approved a generic — why can’t I get it at my pharmacy yet?
Why do different websites show different generic release dates?
What does “FDA listed” mean?
What does a patent or protection date mean here?
What does “current Orange Book estimate” mean?
Can a generic come out before the last patent expires?
Can a generic come out after the listed dates?
What is the difference between patents and exclusivity?
Why are there multiple patent dates?
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Meloxicam / Rizatriptan inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 2PP9364507
A modified form of beta-cyclodextrin, a natural sugar-like molecule. It helps dissolve and stabilize drugs in liquid medicines and improves how well the body absorbs certain medications.
-
UNII 2S7830E561
Crospovidone is a synthetic polymer derived from povidone. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the active ingredient can be absorbed.
-
UNII 70097M6I30
Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
-
UNII OP1R32D61U
Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
-
UNII 3WJQ0SDW1A
Polyethylene glycol is a synthetic liquid or solid polymer used in medicines as a solvent, lubricant, and humectant. It helps dissolve active ingredients, reduces friction during manufacturing, and retains moisture in the final product.
-
UNII 532B59J990
Polyvinyl alcohol is a synthetic polymer made from plant-derived materials. It's used as a binder to hold ingredients together, a film-former in coatings, and a thickener in liquid formulations.
-
UNII FZ989GH94E
Povidone is a synthetic polymer made from a plastic-like material. It acts as a binder to hold tablet ingredients together and as a disintegrant to help the tablet break apart in your stomach so the medicine can be absorbed.
-
UNII ETJ7Z6XBU4
Silicon dioxide is a naturally occurring mineral used as a glidant and anti-caking agent. It helps powder ingredients flow smoothly and prevents clumping during manufacturing and storage.
-
UNII 8MDF5V39QO
A white powder form of baking soda that acts as a buffer and pH regulator in medicines. It helps maintain the right acid-base balance and may aid tablet disintegration.
-
UNII O8232NY3SJ
A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.
-
UNII 7SEV7J4R1U
A powder made from a naturally occurring mineral. In medicines, talc works as a glidant and anti-caking agent, helping tablets and capsules flow smoothly during manufacturing and preventing clumping.
-
UNII 15FIX9V2JP
Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.
12 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 19, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Axsome Therapeutics, Inc. labeler code 81968
- Auvelity dextromethorphan hydrobromide, bupropion hydrochloride 105 mg; 30 mg Tablet, Multilayer, Extended Release NDC 81968-030-22
- Auvelity dextromethorphan hydrobromide, bupropion hydrochloride 105 mg; 45 mg Tablet, Multilayer, Extended Release NDC 81968-045-14
- AUVELITY dextromethorphan hydrobromide, bupropion hydrochloride Kit NDC 81968-345-01
- Sunosi solriamfetol 75 mg Tablet, Film Coated NDC 81968-350-01
- Sunosi solriamfetol 150 mg Tablet, Film Coated NDC 81968-351-01
- AUVELITY dextromethorphan hydrobromide, bupropion hydrochloride Kit NDC 81968-453-01
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🚨 Boxed Warning ▾
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Risk Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings & Precautions (5.1) ] . SYMBRAVO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications (4) , Warnings & Precautions (5.1) ] .
Gastrointestinal Risk NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events [see Warnings & Precautions (5.2) ] .
WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use (5.1) .
SYMBRAVO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery ( 4 , 5.1 ). NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms.
Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events ( 5.2 ).
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE SYMBRAVO is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use SYMBRAVO should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with SYMBRAVO, the diagnosis of migraine should be reconsidered before SYMBRAVO is administered to treat any subsequent attacks.
SYMBRAVO is not indicated for the preventive treatment of migraine attacks. SYMBRAVO is not indicated for the treatment of cluster headache. SYMBRAVO is a combination of meloxicam (an NSAID) and rizatriptan (a serotonin (5-HT) 1B/1D receptor agonist (triptan)), indicated for the acute treatment of migraine with or without aura in adults ( 1 ).
Limitations of Use SYMBRAVO should only be used where a clear diagnosis of migraine has been established ( 1 ). SYMBRAVO is not indicated for the preventive treatment of migraine ( 1 ). SYMBRAVO is not indicated for the treatment of cluster headache ( 1 ).
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION The recommended dose of SYMBRAVO is one tablet by mouth as needed ( 2.1 ). The maximum daily dose is 20 mg meloxicam and 10 mg rizatriptan (1 tablet) ( 2.1 ).
2.1Recommended Dose The recommended dose of SYMBRAVO is one tablet (containing 20 mg meloxicam and 10 mg rizatriptan) by mouth, as needed for the acute treatment of migraine. The maximum daily dose should not exceed one tablet. The safety and effectiveness of a second dose for the same migraine attack have not been established.
The safety of treating, on average, more than 7 headaches in a 30-day period has not been established. Use for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5) ] .
2.2Administration Swallow SYMBRAVO tablets whole. Do not crush, divide, or chew the tablets. SYMBRAVO can be taken with or without food.
2.3Not Substitutable with Other Formulations of Meloxicam and of Rizatriptan SYMBRAVO tablets have not shown equivalent systemic exposures to other formulations of oral meloxicam and of oral rizatriptan. Therefore, SYMBRAVO tablets are not substitutable with other formulations of oral meloxicam or oral rizatriptan products, even if the milligram strengths are the same. Do not substitute SYMBRAVO with similar dose strengths of other meloxicam or rizatriptan products [see Clinical Pharmacology (12.3) ] .
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Tablets: 20 mg meloxicam and 10 mg rizatriptan, white and modified capsule-shaped, debossed with “MXRZ” on one side and “20/10” on the other. Tablets: 20 mg meloxicam and 10 mg rizatriptan ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS SYMBRAVO is contraindicated in patients with: Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), or other significant underlying cardiovascular disease [see Warnings & Precautions (5.1) ] . Coronary artery vasospasm including Prinzmetal’s angina [see Warnings & Precautions (5.1) ] . In the setting of coronary artery bypass graft (CABG) surgery [see Warnings & Precautions (5.1) ] .
History of stroke or transient ischemic attack (TIA) [see Warnings & Precautions (5.4) ] . Hemiplegic or basilar migraine. Peripheral vascular disease (PVD) [see Warnings & Precautions (5.7) ] .
Ischemic bowel disease [see Warnings & Precautions (5.7) ] . Uncontrolled hypertension [see Warnings & Precautions (5.9) ] . Concomitant use of propranolol [see Drug Interactions (7.1) ] Recent use (i.e., within 24 hours) of an ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-HT1 agonist (e.g., another triptan) [see Drug Interactions (7.1) ] .
Concurrent administration or recent discontinuation (i.e., within 2 weeks) of a MAO-A inhibitor [see Drug Interactions (7.1) , Clinical Pharmacology (12.3) ] . Known hypersensitivity (e.g., anaphylactic reactions and angioedema seen) to SYMBRAVO, meloxicam, rizatriptan, NSAIDs or any of the excipients in SYMBRAVO [see Warnings & Precautions (5.5) , Adverse Reactions (6.2) ] . History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
Severe, sometimes fatal anaphylactic-like reactions to NSAIDs have been reported in such patients [see Warnings & Precautions (5.16 )] . Moderate to severe renal insufficiency in patients who are at risk for renal failure due to volume depletion or who are on dialysis [see Warnings & Precautions (5.11 )]. Ischemic coronary artery disease or other significant underlying cardiovascular disease ( 4 ) Coronary artery vasospasm ( 4 ) In the setting of CABG surgery ( 4 ) History of stroke or transient ischemic attack ( 4 ) Hemiplegic or basilar migraine ( 4 ) Peripheral vascular disease ( 4 ) Ischemic bowel disease ( 4 ) Uncontrolled hypertension ( 4 ) Concomitant use of propranolol ( 4 ) Recent (within 24 hours) use of an ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), another 5-HT 1 agonist (e.g., another triptan) ( 4 ) Concurrent administration or recent discontinuation (i.e., within the past 2 weeks) of a MAO-A inhibitor ( 4 ) Known hypersensitivity to SYMBRAVO, meloxicam, rizatriptan, NSAIDs, triptans, or any of the excipients in SYMBRAVO ( 4 ) History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs ( 4 ) Moderate to severe renal insufficiency in patients who are at risk for renal failure due to volume depletion or who are on dialysis ( 4 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Cardiovascular Thrombotic Events, Myocardial Ischemia, Myocardial Infarction, and Prinzmetal's Angina: Perform cardiac evaluation in patients with multiple cardiovascular risk factors ( 5.1 ). Arrhythmias: Discontinue dosing if arrhythmia occurs ( 5.3 ). Cerebral Hemorrhage, Subarachnoid Hemorrhage, and Stroke: Discontinue dosing if occurs ( 5.4 ).
Anaphylactic Reactions: Seek emergency help if an anaphylactic reaction occurs ( 5.5 ). Chest/Throat/Neck/Jaw Pain, Tightness, Pressure, or Heaviness: Generally not associated with myocardial ischemia; evaluate patients at high risk ( 5.6 ). Gastrointestinal Ischemic Events, Peripheral Vasospastic Reactions: Discontinue dosing if occurs ( 5.7 ).
Hepatotoxicity: Inform patients of warning signs and symptoms of hepatotoxicity. Discontinue if abnormal liver tests persist or worsen or if clinical signs and symptoms of liver disease develop ( 5.8 ). Hypertension: Patients taking some antihypertensive medications may have impaired response to these therapies when taking NSAIDs.
Monitor blood pressure ( 5.9 , 7.1 ). Heart Failure and Edema: Avoid use of SYMBRAVO in patients with severe heart failure unless benefits are expected to outweigh risk of worsening heart failure ( 5.10 ). Renal Toxicity and Hyperkalemia: Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia.
Use is not recommended in patients with moderate to severe renal insufficiency; avoid the use in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function ( 4 , 5.11 ). Serious Skin Reactions: Discontinue SYMBRAVO at first appearance of skin rash or other signs of hypersensitivity ( 5.12 ). Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Discontinue SYMBRAVO and evaluate clinically ( 5.13 ).
Fetal Toxicity: Limit use of NSAIDs, including SYMBRAVO, between about 20 to 30 weeks in pregnancy due to the risk of oligohydramnios/fetal renal dysfunction. Avoid use of NSAIDs in women at about 30 weeks gestation and later in pregnancy due to the risks of oligohydramnios/fetal renal dysfunction and premature closure of the fetal ductus arteriosus ( 5.14 , 8.1 ). Hematologic Toxicity: Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia ( 5.15 , 7.1 ).
Exacerbation of Asthma Related to Aspirin Sensitivity: SYMBRAVO is contraindicated in patients with aspirin-sensitive asthma. Monitor patients with preexisting asthma (without aspirin sensitivity) ( 5.16 ). Medication Overuse Headache: Detoxification may be necessary ( 5.17 ).
Serotonin Syndrome: Discontinue dosing if occurs ( 5.18 ).
5.1Cardiovascular Thrombotic Events and Myocardial Infarction Cardiovascular Thrombotic Events with NSAIDS Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. Based on available data, it is unclear that the risk for CV thrombotic events is similar for all NSAIDs. The relative increase in serious CV thrombotic events over baseline conferred by NSAID use appears to be similar in those with and without known CV disease or risk factors for CV disease.
However, patients with known CV disease or risk factors had a higher absolute incidence of excess serious CV thrombotic events, due to their increased baseline rate. Some observational studies found that this increased risk of serious CV thrombotic events began as early as the first weeks of treatment. The increase in CV thrombotic risk has been observed most consistently at higher doses.
To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Physicians and patients should remain alert for the development of such events, throughout the entire treat… [Excerpted — this section continues on DailyMed.]
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling: Cardiovascular Thrombotic Events and Myocardial Infarction [see Warnings and Precautions (5.1) ] GI Bleeding, Ulceration, and Perforation [see Warnings and Precautions (5.2) ] Arrhythmias [see Warnings and Precautions (5.3) ] Cerebrovascular Events [see Warnings and Precautions (5.4) ] Anaphylactic Reactions [see Warnings and Precautions (5.5)] Chest, Throat, Neck and/or Jaw Pain/Tightness/Pressure [see Warnings and Precautions (5.6) ] Other Vasospasm Reactions [see Warnings and Precautions (5.7) ] Hepatotoxicity [see Warnings and Precautions (5.8) ] Hypertension/Increase in Blood Pressure [see Warnings and Precautions (5.9) ] Heart Failure and Edema [see Warnings and Precautions (5.10) ] Renal Toxicity and Hyperkalemia [see Warnings and Precautions (5.11) ] Serious Skin Reactions [see Warnings and Precautions (5.12)] Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) [see Warnings and Precautions (5.13) ] Fetal Toxicity [see Warnings and Precautions (5.14) ] Hematologic Toxicity [see Warnings and Precautions (5.15) ] Exacerbation of Asthma Related to Aspirin Sensitivity [see Warnings and Precautions (5.16 )] Medication Overuse Headache [see Warnings and Precautions (5.17) ] Serotonin Syndrome [see Warnings and Precautions (5.18) ] Most common adverse reactions (≥1% and greater than placebo) are dizziness and somnolence ( 6.1 ).
To report SUSPECTED ADVERSE REACTIONS, contact Axsome Therapeutics at 1-800-484-1672 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. In two randomized, double-blind, controlled trials in adults with migraine, a total of 581 patients received a single dose of SYMBRAVO after the onset of a migraine attack (Studies 1 and 2) [see Clinical Studies (14) ] .
The most common adverse reactions from these two trials after treatment with SYMBRAVO (incidence ≥1% and greater than placebo) are provided in Table 1. Table 1: Incidence (≥1% and Greater than Placebo) of Adverse Reactions after a Single Dose of SYMBRAVO in Adults (Study 1 and Study 2) SYMBRAVO N=581 a % Rizatriptan 10 mg N=434 b % Meloxicam 20 mg N=433 b % Placebo N=361 a % Somnolence 2 2 2 1 Dizziness 2 2 1 1 a Study 1 and Study 2 pooled b Data from Study 1 only; Study 2 did not include arms with each individual component Long-term safety was assessed in 706 patients dosing intermittently for up to 12 months in an open-label extension trial where patients treated at least 2 migraines per month with SYMBRAVO.
Of these 706 patients, 496 patients were exposed to SYMBRAVO for at least 6 months, and 132 were exposed for at least 12 months, all of whom treated at least 2 migraine attacks per month, on average.
6.2Postmarketing Experience The following adverse reactions have been reported with the individual components of SYMBRAVO, meloxicam and rizatriptan, from postmarketing experience. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Meloxicam Blood and Lymphatic System Disorders: Agranulocytosis Hepatobiliary Disorders: Jaundice; liver failure Psychiatric Disorders: Alterations in mood (such as mood elevation) Renal and Urinary Disorders: Acute urinary retention; interstitial nephritis Reproductive System and Breast Disorders: Infertility female Skin and Subcutaneous Tissue Disorders: Anaphylactic reactions including shock; erythema multiforme; exfoliative dermatitis; Stevens-Johnson syndrome; fixed drug eruption (FDE); toxic epidermal necrolysis [see Warnings and Precautions (5.12)… [Excerpted — this section continues on DailyMed.]
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e.g., warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking SYMBRAVO with drugs that interfere with hemostasis. Concomitant use of SYMBRAVO and analgesic doses of aspirin is not generally recommended ( 7.1 ). ACE Inhibitors, ARBs, or Beta-Blockers: Concomitant use with SYMBRAVO may diminish the antihypertensive effect of these drugs.
Monitor blood pressure ( 7.1 ). ACE Inhibitors and ARBs: Concomitant use with SYMBRAVO in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high-risk patients, monitor for signs of worsening renal function ( 7.1 ).
Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7.1 ). Lithium: Monitor for increases in lithium plasma levels ( 7.1 ) Methotrexate: Monitor for increases methotrexate plasma levels.
( 7.1 ).
7.1Drugs Having Clinically Important Interactions with SYMBRAVO See Table 2 for clinically significant drug interactions with SYMBRAVO [see Clinical Pharmacology (12.3) ] . Table 2: Clinically Important Drug Interactions with SYMBRAVO Drugs That Interfere with Hemostasis Clinical Impact Meloxicam and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of meloxicam and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone.
Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention Monitor patients with concomitant use of SYMBRAVO with anticoagulants (e.g., warfarin), antiplatelet agents (e.g., aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding [see Warnings and Precautions (5.15) ] .
Caution should be used when administering SYMBRAVO with warfarin since patients on warfarin may experience changes in International Normalized Ratio (INR) and an increased risk of bleeding complications when a new medication is introduced. Aspirin Clinical Impact Controlled clinical studies showed that the concomitant use of NSAIDs and analgesic doses of aspirin does not produce any greater therapeutic effect than the use of NSAIDs alone. In a clinical study, the concomitant use of an NSAID and aspirin was associated with a significantly increased incidence of GI adverse reactions as compared to use of the NSAID alone [see Warnings and Precautions (5.2 )].
Intervention Concomitant use of SYMBRAVO and analgesic doses of aspirin is not generally recommended because of the increased risk of bleeding [see Warnings and Precautions (5.15) ] . In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, monitor patients more closely for evidence of GI bleeding [see Warnings and Precautions (5.2) ] . Meloxicam in SYMBRAVO is not a substitute for low dose aspirin for cardiovascular protection.
SSRIs/SNRIs and Serotonin Syndrome Clinical Impact Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs or SNRIs [see Warnings and Precautions (5.18) ]. Intervention SYMBRAVO treatment should be discontinued if serotonin syndrome is suspected. ACE Inhibitors, Angiotensin Receptor Blockers, and Beta-Blockers Clinical Impact NSAIDs may diminish the antihypertensive effect of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or beta blockers.
In patients who are elderly, volume-depleted (including those on diuretic therapy), or have renal impairment, co-administration of an NSAID with ACE inhibitors or ARBs may result in deterioration of renal function, including possible acute renal failu… [Excerpted — this section continues on DailyMed.]
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS Infertility: NSAIDs are associated with reversible infertility. Consider withdrawal of SYMBRAVO in women who have difficulties conceiving ( 8.3 ).
8.1Pregnancy SYMBRAVO has not been studied in pregnant women. However, there are data pertaining to the use of the individual components, meloxicam and rizatriptan during pregnancy. These data are described below.
Risk Summary In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The reported rate of major birth defects among infants born to women with migraine range from 2.2% to 2.9% and the reported rate of miscarriage was 17%, which are similar to rates reported in women without migraine. Meloxicam Use of NSAIDs, including SYMBRAVO, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment.
Because of these risks, limit dose and duration of SYMBRAVO use between about 20 and 30 weeks of gestation, and avoid SYMBRAVO use at about 30 weeks of gestation and later in pregnancy [see Clinical Considerations, Data] . Premature Closure of Fetal Ductus Arteriosus: Use of NSAIDs, including SYMBRAVO, at about 30 weeks gestation or later in pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Oligohydramnios/Neonatal Renal Impairment: Use of NSAIDs at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment.
Data from observational studies regarding other potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive. In animal reproduction studies, embryofetal death was observed in rats and rabbits treated during the period of organogenesis with meloxicam at oral doses equivalent to 0.5 and 4.9 times, respectively, the maximum recommended human dose (MRHD) of 20 mg of meloxicam, based on body surface area (mg/m 2 ). Increased incidence of septal heart defects was observed in rabbits treated throughout embryogenesis with meloxicam at an oral dose equivalent to 59 times the MRHD of 20 mg of meloxicam on a mg/m 2 basis.
In pre- and post-natal reproduction studies, there was an increased incidence of dystocia, delayed parturition, and decreased offspring survival at 0.06 times the MRHD of 20 mg of meloxicam on a mg/m 2 basis. No teratogenic effects were observed in rats and rabbits treated with meloxicam during organogenesis at an oral dose equivalent to 2 and 20 times, respectively, the MRHD of 20 mg of meloxicam on a mg/m 2 basis [se e Data] . Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization.
In animal studies, administration of prostaglandin synthesis inhibitors, such as meloxicam, resulted in increased pre- and post-implantation loss. Prostaglandins also have been shown to have an important role in fetal kidney development. In published animal studies, prostaglandin synthesis inhibitors have been reported to impair kidney development when administered at clinically relevant doses.
Rizatriptan Available human data on the use of rizatriptan in pregnant women are not sufficient to draw conclusions about drug-associated risk for major birth defects and miscarriage. In animal studies, developmental toxicity was observed following oral administration of rizatriptan during pregnancy (decreased fetal body weight in rats) or throughout pregnancy and lactation (increased mortality, decreased body weight, and neurobehavioral impairment in rat offspring) at doses greater than the MRHD of 10 mg rizatriptan on a mg/m 2 basis [see Animal Data] .
Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk In women with migraine,… [Excerpted — this section continues on DailyMed.]
🤰 Pregnancy ▾
8.1Pregnancy SYMBRAVO has not been studied in pregnant women. However, there are data pertaining to the use of the individual components, meloxicam and rizatriptan during pregnancy. These data are described below.
Risk Summary In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The reported rate of major birth defects among infants born to women with migraine range from 2.2% to 2.9% and the reported rate of miscarriage was 17%, which are similar to rates reported in women without migraine. Meloxicam Use of NSAIDs, including SYMBRAVO, can cause premature closure of the fetal ductus arteriosus and fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment.
Because of these risks, limit dose and duration of SYMBRAVO use between about 20 and 30 weeks of gestation, and avoid SYMBRAVO use at about 30 weeks of gestation and later in pregnancy [see Clinical Considerations, Data] . Premature Closure of Fetal Ductus Arteriosus: Use of NSAIDs, including SYMBRAVO, at about 30 weeks gestation or later in pregnancy increases the risk of premature closure of the fetal ductus arteriosus. Oligohydramnios/Neonatal Renal Impairment: Use of NSAIDs at about 20 weeks gestation or later in pregnancy has been associated with cases of fetal renal dysfunction leading to oligohydramnios, and in some cases, neonatal renal impairment.
Data from observational studies regarding other potential embryofetal risks of NSAID use in women in the first or second trimesters of pregnancy are inconclusive. In animal reproduction studies, embryofetal death was observed in rats and rabbits treated during the period of organogenesis with meloxicam at oral doses equivalent to 0.5 and 4.9 times, respectively, the maximum recommended human dose (MRHD) of 20 mg of meloxicam, based on body surface area (mg/m 2 ). Increased incidence of septal heart defects was observed in rabbits treated throughout embryogenesis with meloxicam at an oral dose equivalent to 59 times the MRHD of 20 mg of meloxicam on a mg/m 2 basis.
In pre- and post-natal reproduction studies, there was an increased incidence of dystocia, delayed parturition, and decreased offspring survival at 0.06 times the MRHD of 20 mg of meloxicam on a mg/m 2 basis. No teratogenic effects were observed in rats and rabbits treated with meloxicam during organogenesis at an oral dose equivalent to 2 and 20 times, respectively, the MRHD of 20 mg of meloxicam on a mg/m 2 basis [se e Data] . Based on animal data, prostaglandins have been shown to have an important role in endometrial vascular permeability, blastocyst implantation, and decidualization.
In animal studies, administration of prostaglandin synthesis inhibitors, such as meloxicam, resulted in increased pre- and post-implantation loss. Prostaglandins also have been shown to have an important role in fetal kidney development. In published animal studies, prostaglandin synthesis inhibitors have been reported to impair kidney development when administered at clinically relevant doses.
Rizatriptan Available human data on the use of rizatriptan in pregnant women are not sufficient to draw conclusions about drug-associated risk for major birth defects and miscarriage. In animal studies, developmental toxicity was observed following oral administration of rizatriptan during pregnancy (decreased fetal body weight in rats) or throughout pregnancy and lactation (increased mortality, decreased body weight, and neurobehavioral impairment in rat offspring) at doses greater than the MRHD of 10 mg rizatriptan on a mg/m 2 basis [see Animal Data] .
Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk In women with migraine, there is an increased risk of adverse perinatal outcomes in the mother, including pre-eclampsia and gestational hypertension. Fetal/Neonatal Adverse Reactions Premature Closure… [Excerpted — this section continues on DailyMed.]
🧒 Pediatric Use ▾
8.4Pediatric Use Safety and effectiveness of SYMBRAVO in pediatric patients have not been established.
🧓 Geriatric Use ▾
8.5Geriatric Use Clinical studies of SYMBRAVO did not include subjects aged 65 and over to determine whether they respond differently from younger subjects. Elderly patients, compared to younger patients, are at greater risk for NSAID-associated serious cardiovascular, gastrointestinal, hepatic, and/or renal adverse reactions. If the anticipated benefit for the elderly patient outweighs these potential risks, treat for the fewest number of days per month, as needed, and monitor patients for adverse effects [see Warnings and Precautions (5.1 , 5.2 , 5.8 , 5.11 )] .
Geriatric patients who have other cardiovascular risk factors (e.g., diabetes, hypertension, smoking, obesity, strong family history of coronary artery disease) should have a cardiovascular evaluation prior to receiving SYMBRAVO [see Warnings and Precautions (5.1 , 5.9 )] .
🆘 Overdosage ▾
10 OVERDOSAGE No overdoses of SYMBRAVO were reported during clinical trials in adults. Evaluation and treatment of SYMBRAVO overdose is based on experience with the individual components, meloxicam and rizatriptan. In case of an overdosage, discontinue SYMBRAVO and contact a regional poison control center at 1-800-222-1222.
Overdose of Meloxicam Symptoms following acute meloxicam overdoses have been typically limited to lethargy, drowsiness, nausea, vomiting, and epigastric pain, which have been generally reversible with supportive care. Gastrointestinal bleeding has occurred. Hypertension, acute renal failure, respiratory depression and coma have occurred, but were rare [see Warnings and Precautions (5.2 , 5.9 , 5.11 , 5.15 )] .
Manage patients with symptomatic and supportive care following a meloxicam overdosage. There are no specific antidotes. Consider emesis and/or activated charcoal (60 to 100 grams in adults, 1 to 2 grams per kg of body weight in pediatric patients) and/or osmotic cathartic in symptomatic patients seen within four hours of ingestion or in patients with a large overdosage (5 to 10 times the recommended dosage).
Forced diuresis, alkalinization of urine, hemodialysis, or hemoperfusion may be employed but are not likely to be useful due to high protein binding. There is limited experience with meloxicam overdose. In four reported cases of meloxicam overdose, patients took 6- to 11-times the highest available oral dose of meloxicam tablets (15 mg); all recovered.
Cholestyramine is known to accelerate the clearance of meloxicam. Accelerated removal of meloxicam by 4 g doses of cholestyramine given three times a day was demonstrated in a clinical trial. Administration of cholestyramine may be useful following an overdosage.
Overdose of Rizatriptan In a clinical pharmacology study in which 12 adult subjects received rizatriptan at total cumulative doses of 80 mg (given within four hours), two of the subjects experienced syncope, dizziness, bradycardia including third degree AV block, vomiting, and/or incontinence. Based on the pharmacology of rizatriptan, hypertension or myocardial ischemia could occur after overdosage. Gastrointestinal decontamination, (i.e., gastric lavage followed by activated charcoal) should be considered in patients suspected of an overdose with rizatriptan.
Clinical and electrocardiographic monitoring should be continued for at least 12 hours, even if clinical symptoms are not observed. The effects of hemo- or peritoneal dialysis on serum concentrations of rizatriptan are unknown.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action SYMBRAVO contains meloxicam and rizatriptan. Meloxicam has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of meloxicam, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).
Meloxicam is a potent inhibitor of prostaglandin synthesis in vitro. Meloxicam concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models.
Prostaglandins are mediators of inflammation. Because meloxicam is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. Rizatriptan binds with high affinity to human cloned 5-HT 1B/1D receptors.
Rizatriptan presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT 1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.
12.2Pharmacodynamics Cardiac Electrophysiology Rizatriptan The effects of rizatriptan on QT prolongation have not been studied; however, arrhythmias have occurred after administration of 5-HT 1 agonists [see Warnings and Precautions (5.3) ] . Blood Pressure Rizatriptan Significant elevation in blood pressure, including hypertensive crisis, has been reported in patients treated with rizatriptan, with and without a history of hypertension [see Warnings and Precautions (5.9) ] .
12.3Pharmacokinetics SYMBRAVO is a combination of rizatriptan and meloxicam. Meloxicam when given as SYMBRAVO has a mean C max of approximately 2,900 ng/mL and a mean AUC 0-24 of approximately 33,000 ng*hr/mL. Rizatriptan when given as SYMBRAVO has a mean C max of 32 ng/mL and a mean AUC 0-24 of 83 ng*hr/mL.
Absorption After oral administration of a single dose of SYMBRAVO under fasted conditions, the median T max for the meloxicam component is 0.88 hours, which is less than oral meloxicam tablets (T max of 4-5 hours). The median T max for the rizatriptan component is 0.75 hours. Effect of Food The exposures of meloxicam and rizatriptan were comparable after administration of SYMBRAVO in the fasted and fed states.Administration of SYMBRAVO after a high-fat, high-calorie meal decreased the exposures of meloxicam by approximately 7% for AUC 0-24 and 27% for C max and increased the AUC 0-24 of rizatriptan by approximately 10% with no significant change in C max .
Food intake delayed the time to maximal plasma concentration for both meloxicam (from 0.88 hours to 5 hours) and rizatriptan (from 0.75 hours to 1.5 hours). Therapeutic concentrations of meloxicam were achieved within 1.5 hours with co-administration of food [see Dosage and Administration (2.2) ] . Distribution Meloxicam The apparent volume of distribution during the terminal elimination phase (Vz) of meloxicam is approximately 10 L.
Meloxicam is approximately 99.4% bound to human plasma proteins (primarily albumin) within the therapeutic dose range. The fraction of protein binding is independent of drug concentration, over the clinically relevant concentration range, but decreases to approximately 99% in patients with renal disease. Meloxicam penetration into human red blood cells, after oral dosing, is less than 10%.
Following a radiolabeled dose, over 90% of the radioactivity detected in the plasma was present as unchanged meloxicam. Rizatriptan The mean volume of distribution of rizatriptan is approximately 140 liters in male subjects and 110 liters in female subjects. Rizatriptan is minimally bound (14%) to plasma proteins.
Elimination Metabolism Meloxicam Meloxicam is extensively metabolized in the liver. Meloxicam metabolites include 5'-carboxy meloxicam (60% of dose), from cytochrome P450 (CYP) mediated metabolism formed by oxidation of an intermediate metabolite, 5'-hydroxymethyl meloxicam, which is also excreted to a lesser extent (9% of dose).… [Excerpted — this section continues on DailyMed.]
🧬 Mechanism of Action ▾
12.1Mechanism of Action SYMBRAVO contains meloxicam and rizatriptan. Meloxicam has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of meloxicam, like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).
Meloxicam is a potent inhibitor of prostaglandin synthesis in vitro. Meloxicam concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models.
Prostaglandins are mediators of inflammation. Because meloxicam is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues. Rizatriptan binds with high affinity to human cloned 5-HT 1B/1D receptors.
Rizatriptan presumably exerts its therapeutic effects in the treatment of migraine headache by binding to 5-HT 1B/1D receptors located on intracranial blood vessels and sensory nerves of the trigeminal system.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1How Supplied SYMBRAVO tablets are white, modified capsule-shaped, film-coated and debossed with "MXRZ" on one side and "20/10" on the other. SYMBRAVO is supplied in the following package configuration: Package Configuration Strength NDC Code Bottles of 9 tablets meloxicam 20 mg and rizatriptan 10 mg 81968-020-09
16.2Storage and Handling Store SYMBRAVO in the original bottle at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature] .
📋 Description ▾
11 DESCRIPTION SYMBRAVO contains meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), and rizatriptan (as rizatriptan benzoate), a selective 5-HT 1B/1D receptor agonist. Meloxicam Meloxicam has the molecular formula C 14 H 13 N 3 O 4 S 2 and is chemically designated as 4-hydroxy-2-methyl-N-(5 methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide. It has a molecular weight of 351.4 g/mole.
The structural formula is: Meloxicam is a pastel yellow solid, practically insoluble in water, with higher solubility observed in strong acids and bases. It is very slightly soluble in methanol. Meloxicam has an apparent partition coefficient (log P) = 0.1 in n-octanol/buffer pH 7.4.
Meloxicam has pKa values of 1.1 and 4.2. Rizatriptan Rizatriptan benzoate has the molecular formula C 15 H 19 N 5 · C 7 H 6 O 2 and is chemically designated as N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H indole-3 ethanamine monobenzoate. The molecular weight of the free base rizatriptan is 269.4 g/mole.
The structural formula is: Rizatriptan benzoate is a white to off-white, crystalline solid that is soluble in water at about 42 mg per mL (expressed as free base) at 25°C. Each SYMBRAVO tablet for oral administration contains 20 mg of meloxicam and 10 mg of rizatriptan (equivalent to 14.5 mg of rizatriptan benzoate). Each tablet also contains the excipients colloidal silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, partially hydrolyzed polyvinyl alcohol, polyethylene glycol, povidone, pregelatinized starch, sodium bicarbonate, sulfobutyl-ether-ß-cyclodextrin sodium, talc, and titanium dioxide.
Structure Structure
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Cardiovascular Thrombotic Effects Advise patients to be alert for the symptoms of cardiovascular thrombotic events, including chest pain, shortness of breath, weakness, or slurring of speech, and to report any of these symptoms to their healthcare provider immediately [see Warnings and Precautions (5.1) ] . Risk of Myocardial Ischemia and/or Infarction, Prinzmetal’s Angina, Other Vasospasm-Related Events, and Cerebrovascular Events Inform patients that rizatriptan, a component of SYMBRAVO, may cause serious cardiovascular side effects such as myocardial infarction or stroke.
Although serious cardiovascular events can occur without warning symptoms, patients should be alert for the signs and symptoms of chest pain, shortness of breath, weakness, slurring of speech, and should ask for medical advice when observing any indicative sign or symptoms. Patients should be apprised of the importance of this follow-up [see Warnings and Precautions (5.1 , 5.3 , 5.4 , 5.6 , 5.7 )] . Gastrointestinal Bleeding, Ulceration, and Perforation Advise patients to report symptoms of ulcerations and bleeding, including epigastric pain, dyspepsia, melena, and hematemesis to their healthcare provider.
In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, inform patients of the increased risk for the signs and symptoms of GI bleeding [see Warnings and Precautions (5.2) ] . Anaphylactic Reactions Inform patients of the signs of an anaphylactic reaction (e.g., difficulty breathing, swelling of the face or throat). Instruct patients to seek immediate emergency help if these occur [see Contraindications (4) and Warnings and Precautions (5.5 , 5.16) ] .
Hepatotoxicity Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, diarrhea, pruritus, jaundice, right upper quadrant tenderness, and “flu-like” symptoms). If these occur, instruct patients to stop SYMBRAVO and seek immediate medical therapy [see Warnings and Precautions (5.8) ] . Heart Failure and Edema Advise patients to be alert for the symptoms of congestive heart failure including shortness of breath, unexplained weight gain, or edema and to contact their healthcare provider if such symptoms occur [see Warnings and Precautions (5.10) ] .
Serious Skin Reactions, including DRESS Advise patients to stop SYMBRAVO immediately if they develop any type of rash or fever and to contact their healthcare provider as soon as possible [see Contraindications (4) , Warnings and Precautions (5.12 , 5.13 )] . Female Fertility Advise females of reproductive potential who desire pregnancy that meloxicam, a component of SYMBRAVO, may be associated with a reversible delay in ovulation [see Use in Specific Populations (8.3) ] . Lactation Advise patients to notify their healthcare provider if they are breastfeeding or plan to breastfeed [see Use in Specific Populations (8.2 )] .
Fetal Toxicity Inform pregnant women to avoid use of SYMBRAVO and other NSAIDs starting at 30 weeks gestation because of the risk of the premature closing of the fetal ductus arteriosus. If treatment with SYMBRAVO is needed for a pregnant woman between about 20 to 30 weeks gestation, advise her that she may need to be monitored for oligohydramnios, if treatment continues for longer than 48 hours [see Warnings and Precautions (5.14) , Use in Specific Populations (8.1) ] . Avoid Concomitant Use of NSAIDs Inform patients that the concomitant use of SYMBRAVO with other NSAIDs or salicylates (e.g., diflunisal, salsalate) is not recommended due to the increased risk of gastrointestinal toxicity, and little or no increase in efficacy [see Warnings and Precautions (5.2) , Drug Interactions (7.1) ] .
Alert patients that NSAIDs may be present in “over the counter” medications for treatment of colds, fever, or insomnia. Use of NSAIDs and Low-Dose Aspirin Inform patients not t… [Excerpted — this section continues on DailyMed.]
💬 Medication Guide ▾
MEDICATION GUIDE SYMBRAVO ® (sim-BRAH-voh) (meloxicam-rizatriptan) tablets, for oral use What is the most important information I should know about SYMBRAVO? SYMBRAVO contains 2 medicines: meloxicam (a nonsteroidal anti-inflammatory drug [NSAID]) and rizatriptan (a triptan). NSAIDs, including SYMBRAVO, can cause serious side effects, including: Increased risk of a heart attack or stroke that can lead to death.
This risk may happen early in treatment and may increase: with increasing doses of NSAIDs with longer use of NSAIDs Do not take SYMBRAVO right before or after a heart surgery called a “coronary artery bypass graft (CABG).” Avoid taking SYMBRAVO after a recent heart attack unless your healthcare provider tells you to. You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack. Stop taking SYMBRAVO and get emergency help right away if you have any of the following symptoms of a heart attack or stroke: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw pain or discomfort in your arms, back, neck, jaw, or stomach shortness of breath with or without chest discomfort breaking out in a cold sweat nausea or vomiting feeling lightheaded weakness in one part or on side of your body slurred speech SYMBRAVO is not for people with risk factors for heart disease unless a heart exam is done and shows no problem.
You have a higher risk for heart disease if you: have high blood pressure have high cholesterol levels smoke are overweight have diabetes have a family history of diabetes Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach, and intestines: anytime during use without warning symptoms that may cause death The risk of getting an ulcer or bleeding increases with: past history of stomach ulcers, or stomach or intestinal bleeding with use of NSAIDs taking medicines called “corticosteroids”, “anticoagulants”, “SSRIs” or “SNRIs” (antidepressants), or aspirin (an antiplatelet) increasing doses of NSAIDs older age longer use of NSAIDs poor health smoking advanced liver disease drinking alcohol bleeding problems SYMBRAVO may cause serious allergic reactions or serious skin reactions that can be life-threatening.
Stop taking SYMBRAVO and get emergency help right away if you develop: sudden wheezing swelling of your lips, tongue, throat or body rash fainting problems breathing or swallowing reddening of your skin with blisters or peeling blisters or bleeding of your lips, eye lids, mouth, nose, or genitals SYMBRAVO should only be used: exactly as prescribed for the shortest time needed SYMBRAVO already contains an NSAID (meloxicam). Do not use SYMBRAVO with other medicines to lessen pain or fever or with other medicines for colds or sleeping problems without talking to your healthcare provider first, because they may contain an NSAID also.
What is SYMBRAVO? SYMBRAVO is a combination of meloxicam (an NSAID) and rizatriptan (a triptan). SYMBRAVO is used to treat acute migraine headaches with or without aura in adults.
SYMBRAVO is not for the treatment of other types of migraines such as hemiplegic (that make you unable to move on one side of your body) or basilar (rare form of migraine with aura). SYMBRAVO is not to be used to prevent or decrease the number of migraine headaches you have. It is not known if SYMBRAVO is safe and effective for the treatment of cluster headaches.
It is not known if SYMBRAVO is safe and effective in children. Who should not take SYMBRAVO? Do not take SYMBRAVO if you: have or have had heart problems. right before or after heart bypass surgery. have or have had a stroke or a transient ischemic attack (TIA). have or have had blood vessel problems, including ischemic bowel disease. have or had hemiplegic migraines or basilar migraines. narrowing of blood… [Excerpted — this section continues on DailyMed.]
🧬 Pharmacokinetics ▾
12.3Pharmacokinetics SYMBRAVO is a combination of rizatriptan and meloxicam. Meloxicam when given as SYMBRAVO has a mean C max of approximately 2,900 ng/mL and a mean AUC 0-24 of approximately 33,000 ng*hr/mL. Rizatriptan when given as SYMBRAVO has a mean C max of 32 ng/mL and a mean AUC 0-24 of 83 ng*hr/mL.
Absorption After oral administration of a single dose of SYMBRAVO under fasted conditions, the median T max for the meloxicam component is 0.88 hours, which is less than oral meloxicam tablets (T max of 4-5 hours). The median T max for the rizatriptan component is 0.75 hours. Effect of Food The exposures of meloxicam and rizatriptan were comparable after administration of SYMBRAVO in the fasted and fed states.Administration of SYMBRAVO after a high-fat, high-calorie meal decreased the exposures of meloxicam by approximately 7% for AUC 0-24 and 27% for C max and increased the AUC 0-24 of rizatriptan by approximately 10% with no significant change in C max .
Food intake delayed the time to maximal plasma concentration for both meloxicam (from 0.88 hours to 5 hours) and rizatriptan (from 0.75 hours to 1.5 hours). Therapeutic concentrations of meloxicam were achieved within 1.5 hours with co-administration of food [see Dosage and Administration (2.2) ] . Distribution Meloxicam The apparent volume of distribution during the terminal elimination phase (Vz) of meloxicam is approximately 10 L.
Meloxicam is approximately 99.4% bound to human plasma proteins (primarily albumin) within the therapeutic dose range. The fraction of protein binding is independent of drug concentration, over the clinically relevant concentration range, but decreases to approximately 99% in patients with renal disease. Meloxicam penetration into human red blood cells, after oral dosing, is less than 10%.
Following a radiolabeled dose, over 90% of the radioactivity detected in the plasma was present as unchanged meloxicam. Rizatriptan The mean volume of distribution of rizatriptan is approximately 140 liters in male subjects and 110 liters in female subjects. Rizatriptan is minimally bound (14%) to plasma proteins.
Elimination Metabolism Meloxicam Meloxicam is extensively metabolized in the liver. Meloxicam metabolites include 5'-carboxy meloxicam (60% of dose), from cytochrome P450 (CYP) mediated metabolism formed by oxidation of an intermediate metabolite, 5'-hydroxymethyl meloxicam, which is also excreted to a lesser extent (9% of dose). In vitro studies indicate that CYP2C9 plays an important role in this metabolic pathway with a minor contribution of the CYP3A4 isozyme.
Patients’ peroxidase activity is probably responsible for the other two metabolites, which account for 16% and 4% of the administered dose, respectively. The four metabolites are not known to have any in vivo pharmacological activity. Rizatriptan The primary route of rizatriptan metabolism is via oxidative deamination by monoamine oxidase-A (MAO-A) to the indole acetic acid metabolite, which is not active at the 5-HT 1B/1D receptor.
N-monodesmethyl-rizatriptan, a metabolite with activity similar to that of the parent compound at the 5-HT 1B/1D receptor, is formed to a minor degree. Plasma concentrations of N-monodesmethyl-rizatriptan are approximately 14% of those of parent compound, and it is eliminated at a similar rate. Other minor metabolites, the N-oxide, the 6-hydroxy compound, and the sulfate conjugate of the 6-hydroxy metabolite are not active at the 5-HT 1B/1D receptor.
After administration of SYMBRAVO, mean elimination half-life is approximately 18 hours for meloxicam and 2 hours for rizatriptan. Excretion Meloxicam Meloxicam excretion is predominantly in the form of metabolites and occurs to equal extents in the urine and feces. Only traces of the unchanged parent compound are excreted in the urine (0.2%) and feces (1.6%).
The extent of the urinary excretion was confirmed for unlabeled multiple 7.5 mg doses: 0.5%, 6%, and 13% of the dose were found in urine in the form of me… [Excerpted — this section continues on DailyMed.]
🧬 Pharmacodynamics ▾
12.2Pharmacodynamics Cardiac Electrophysiology Rizatriptan The effects of rizatriptan on QT prolongation have not been studied; however, arrhythmias have occurred after administration of 5-HT 1 agonists [see Warnings and Precautions (5.3) ] . Blood Pressure Rizatriptan Significant elevation in blood pressure, including hypertensive crisis, has been reported in patients treated with rizatriptan, with and without a history of hypertension [see Warnings and Precautions (5.9) ] .
🔬 Clinical Studies ▾
14 CLINICAL STUDIES Study 1: Efficacy Trial The efficacy of SYMBRAVO for the acute treatment of migraine with or without aura in adults was demonstrated in one randomized, double-blind, controlled trial [Study 1 ( NCT03896009 )]. SYMBRAVO demonstrated an effect on headache pain freedom and most bothersome symptom (MBS) freedom at two hours after dosing, compared to placebo. Among patients who selected an MBS, the most commonly selected symptom was photophobia (61%), followed by nausea (20%), and phonophobia (19%).
In Study 1, 1,594 patients with a history of migraine with or without aura, according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria, were randomized to receive either SYMBRAVO (N=456), 10 mg rizatriptan (N=456), 20 mg meloxicam (matching the formulation of the meloxicam used in SYMBRAVO) (N=455), or placebo (N=227). Patients were instructed to treat a migraine of moderate to severe pain intensity with a single dose of medication. Rescue medication (including triptans and NSAIDs) was allowed 2 hours after the initial treatment; however, ergots were not allowed within 24 hours before or after study drug administration, and opioids were not allowed for the duration of the study.
Patients were 83% female and 17% male, predominantly White (77%), with a mean age of 41.2 years (range 18-67). Approximately 7% of patients were taking preventive medications for migraine at baseline. The primary efficacy analyses were conducted in patients who treated a migraine with moderate to severe pain.
Pain freedom was defined as a reduction of moderate or severe headache pain to no headache pain, and MBS freedom was defined as the absence of the self-identified MBS (i.e., photophobia, phonophobia, or nausea). The percentage of patients achieving headache pain freedom and MBS freedom 2 hours after a single dose was statistically significantly greater among patients who received SYMBRAVO compared to those who received placebo (Table 3). The key secondary endpoint of percentage of patients who experienced sustained pain freedom up to 24 hours (pain free from 2 hours through 24 hours postdose without use of other medications) was statistically significantly greater among patients who received a single dose of SYMBRAVO (16.1%) compared to those who received meloxicam (9%; p=0.001), or rizatriptan (11%; p=0.038).
Additional secondary endpoints included pain relief (reduction in migraine pain intensity from moderate or severe to mild or no headache pain) and the ability to perform normal daily activities at 2 hours after dosing. The ability to perform normal daily activities at two hours after dosing was derived from a single item questionnaire, which asked patients to select one response on a 4-point scale; normal function, mild impairment, severe impairment, or required bedrest. A statistically significantly greater percentage of participants who received SYMBRAVO achieved pain relief at 2 hours after dosing and were able to perform normal daily activities at 2 hours after dosing when compared to placebo (Table 3).
Table 3: Migraine Efficacy Endpoints for SYMBRAVO (Study 1) a SYMBRAVO (N=428) Rizatriptan (N=419) Meloxicam (N=421) Placebo (N=209) Co-Primary Endpoints Pain Free at Hour 2 19.9% b 17.4% 11.6% 6.7% MBS Free at Hour 2 36.9% b 35.8% 32.5% 24.4% Key-Secondary Endpoint 24 Hour Sustained Pain Freedom 16.1% c 11.2% 8.8% 5.3% Other Secondary Endpoints Pain Relief at Hour 2 69.2% b 65.6% 62.0% 54.5% Able to Perform Normal Daily Activities at Hour 2 32.0% b 30.3% 24.5% 21.1% a p- values provided only for prespecified comparisons. b p <0.01 versus placebo. c p <0.05 versus rizatriptan, and meloxicam.
Use of rescue medication within 24 hours was also evaluated. There was a numerically lower percentage of patients who received SYMBRAVO and used a rescue medication within 24 hours (23%) vs rizatriptan (35%), meloxicam (35%), and placebo (44%). Figure 1 presents the percentage of patients achieving migra… [Excerpted — this section continues on DailyMed.]
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility The potential effects of the SYMBRAVO on carcinogenesis, mutagenesis, or impairment of fertility have not been studied. However, the individual components, meloxicam and rizatriptan, have been studied and the results of these studies are described below. Carcinogenesis Meloxicam There was no increase in tumor incidence in long-term carcinogenicity studies in rats (104 weeks) and mice (99 weeks) administered meloxicam at oral doses up to 0.8 mg/kg/day in rats and up to 8.0 mg/kg/day in mice (up to 0.4 and 2 times, respectively, the MRHD of 20 mg/day of meloxicam on a mg/m 2 basis).
Rizatriptan Oral carcinogenicity studies of rizatriptan were conducted in mice (100 weeks) and rats (106 weeks) at doses of up to 125 mg/kg/day (up to 60 and 120 times, respectively, the MRHD of 10 mg of rizatriptan on a mg/m 2 basis). There was no evidence of an increase in tumor incidence related to rizatriptan in either species. Mutagenesis Meloxicam Meloxicam was not mutagenic in an Ames assay.
Meloxicam was not clastogenic in an in vitro chromosome aberration assay with human lymphocytes and an in vivo micronucleus assay in mouse bone marrow. Rizatriptan Rizatriptan was neither mutagenic nor clastogenic in a battery of in vitro and in vivo genetic toxicity studies, including: the microbial mutagenesis (Ames) assay, in vitro mammalian cell mutagenesis and chromosomal aberration assays, and the in vivo chromosomal aberration assay in mouse. Impairment of fertility Meloxicam Meloxicam did not impair male and female fertility in rats at oral doses up to 9 mg/kg/day in males and 5 mg/kg/day in females (up to 4.4 and 2.4 times greater, respectively, than the MRHD of 20 mg of meloxicam on a mg/m 2 basis).
In a published study, oral administration of 1 mg/kg (0.5 times the MRHD on a mg/m 2 basis) meloxicam to male rats for 35 days resulted in decreased sperm count and motility and histopathological evidence of testicular degeneration. The clinical relevance of these findings is unknown. Rizatriptan Oral administration of rizatriptan (0, 2, 10, or 100 mg/kg/day) to female rats prior to and during mating and continuing throughout gestation and lactation resulted in no effect on fertility; however, altered estrous cyclicity and delays in time to mating were observed at the highest dose tested.
The no-effect dose for reproductive toxicity was approximately 10 mg/kg/day (10 times the MRHD of 10 mg rizatriptan on a mg/m 2 basis). Oral administration of rizatriptan (0, 5, 35, or 250 mg/kg/day) to male rats prior to and during mating resulted in no impairment of fertility or reproductive performance. The highest dose tested (250 mg/kg/day) was 242 times the MRHD of 10 mg rizatriptan on a mg/m 2 basis.
📄 Package Label / Principal Display Panel ▾
Principal Display Panel - NDC: 81968-020-09 - 9-count Bottle NDC 81968-020-09 Rx only 9 Tablets For oral use SYMBRAVO ® (meloxicam and rizatriptan) tablets 20 mg/10 mg Attention: Dispense with the accompanying Medication Guide to each patient. 9-ct Bottle Label
Principal Display Panel - NDC: 81968-020-03 - 3-count Physician Sample Rx Only NDC 81968-020-03 SYMBRAVO ® (meloxicam and rizatriptan) tablets 20 mg/10 mg Patient Sample 3 Tablets For oral use Not or Sale. Dispense with Medication Guide 3-ct Sample Bottle Label 3-ct Sample Carton Label
Principal Display Panel - NDC: 81968-020-02 - 2-count Physician Sample Rx Only NDC 81968-020-02 SYMBRAVO® (meloxicam and rizatriptan) tablets 20 mg/10 mg Patient Sample 2 Tablets For oral use Not or Sale. Dispense with Medication Guide 2-count Sample Carton Label 2-count Sampel Bottle Label
Medicaid utilization by pack size
Medicare Part D spend CMS · PART D · 2026 (Q1)
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |